The review discusses 58 peptides in different clinical phases, indicating a strong pipeline of peptide therapies targeting PPIs. Co-formulation with other permeation enhancers, enzyme inhibitors, and hydrogels have also been used to allow the oral administration of other peptide medications, for example octreotide and insulin, that are now in clinical https://homers197rle9.idblogmaker.com/profile